Targeted attenuation of elevated histone marks at SNCA alleviates α‐synuclein in Parkinson's disease

EMBO Mol Med (2021)13:e12188    https://doi.org/10.15252/emmm.202012188

1. Guhathakurta S, Kim J, Adams L, Basu S, Song MK, Adler E, et al. Targeted attenuation of elevated histone marks at SNCA alleviates alpha-synuclein in Parkinson's disease. EMBO Mol Med. 2021:e12188.
2. Cristovao AC, Campos FL, Je G, Esteves M, Guhathakurta S, Yang L, et al. Characterization of a Parkinson's disease rat model using an upgraded paraquat exposure paradigm. Eur J Neurosci. 2020;52(4):3242-55.
3. Je G, Guhathakurta S, Yun SP, Ko HS, and Kim YS. A novel extended form of alpha-synuclein 3'UTR in the human brain. Mol Brain. 2018;11(1):29.
4. Evangelista BA, Kim YS, and Kolpashchikov DM. FaptaSyme: A Strategy for Converting a Monomer/Oligomer-Nonselective Aptameric Sensor into an Oligomer-Selective One. Chembiochem : a European journal of chemical biology. 2018.
5. Je G, and Kim YS. Mitochondrial ROS-mediated post-transcriptional regulation of alpha-synuclein through miR-7 and miR-153. Neurosci Lett. 2017;661:132-6.
6. Je G, Croop B, Basu S, Tang J, Han KY, and Kim YS. Endogenous Alpha-Synuclein Protein Analysis from Human Brain Tissues Using Single-Molecule Pull-Down Assay. Anal Chem. 2017;89(24):13044-8.
7. Guhathakurta S, Evangelista BA, Ghosh S, Basu S, and Kim YS. Hypomethylation of intron1 of alpha-synuclein gene does not correlate with Parkinson's disease. Mol Brain. 2017;10(1):6.
8. Guhathakurta S, Bok E, Evangelista BA, and Kim YS. Deregulation of alpha-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA. Prog Neurobiol. 2017.
9. Basu S, Adams L, Guhathakurta S, and Kim YS. A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3'end using CRISPR-Cas9 genome editing technique. Sci Rep. 2017;8:45883.
10. Rocha SM, Saraiva T, Cristovao AC, Ferreira R, Santos T, Esteves M, et al. Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation. J Neuroinflammation. 2016;13(1):137.
11. Bae YS, Choi S, Park JJ, Joo JH, Cui M, Cho H, et al. Synthesis and biological evaluation of 3-substituted 5-benzylidene-1-methyl-2-thiohydantoins as potent NADPH oxidase (NOX) inhibitors. Bioorg Med Chem. 2016.
12. Nam JH, Park ES, Won SY, Lee YA, Kim KI, Jeong JY, et al. TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. Brain : a journal of neurology. 2015.
13. Choi DH, Kim JH, Lee KH, Kim HY, Kim YS, Choi WS, et al. Role of neuronal NADPH oxidase 1 in the peri-infarct regions after stroke. PloS one. 2015;10(1):e0116814.
14. Basu S, Je G, and Kim YS. Transcriptional mutagenesis by 8-oxodG in alpha-synuclein aggregation and the pathogenesis of Parkinson's disease. Experimental & molecular medicine. 2015;47:e179.
15. Ha JY, Kim JS, Kang YH, Bok E, Kim YS, and Son JH. Tnfaip8 l1/Oxi-beta binds to FBXW5, increasing autophagy through activation of TSC2 in a Parkinson's disease model. Journal of neurochemistry. 2014.
16. Choi DH, Lee KH, Kim JH, Seo JH, Kim HY, Shin CY, et al. NADPH Oxidase 1, a Novel Molecular Source of ROS in Hippocampal Neuronal Death in Vascular Dementia. Antioxidants & redox signaling. 2014.
17. Choi DH, Kim JH, Seo JH, Lee J, Choi WS, and Kim YS. Matrix metalloproteinase-3 causes dopaminergic neuronal death through Nox1-regenerated oxidative stress. PloS one. 2014;9(12):e115954.
18. Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, et al. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2013;10(1):143-53.
19. Cristovao AC, Barata J, Je G, and Kim YS. PKCdelta mediates paraquat-induced Nox1 expression in dopaminergic neurons. Biochemical and biophysical research communications. 2013.
20. Chung YC, Kim YS, Bok E, Yune TY, Maeng S, and Jin BK. MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators of inflammation. 2013;2013:370526.
21. Campos FL, Carvalho MM, Cristovao AC, Je G, Baltazar G, Salgado AJ, et al. Rodent models of Parkinson's disease: beyond the motor symptomatology. Frontiers in behavioral neuroscience. 2013;7:175.
22. Kim YS, and Joh TH. Matrix Metalloproteinases, New Insights into the Understanding of Neurodegenerative Disorders. Biomolecules & therapeutics. 2012;20(2):133-43.
23. Cristovao AC, Guhathakurta S, Bok E, Je G, Yoo SD, Choi DH, et al. NADPH oxidase 1 mediates alpha-synucleinopathy in Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012;32(42):14465-77.
24. Choi DH, Cristovao AC, Guhathakurta S, Lee J, Joh TH, Beal MF, et al. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxidants & redox signaling. 2012;16(10):1033-45.
25. Chaturvedi RK, Hennessey T, Johri A, Tiwari SK, Mishra D, Agarwal S, et al. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. Human molecular genetics. 2012;21(15):3474-88.
26. Huh SH, Chung YC, Piao Y, Jin MY, Son HJ, Yoon NS, et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J Immunol. 2011;187(2):960-9.
27. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology. 2011;60(6):963-74.
28. Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol. 2011;187(12):6508-17.
29. Choi DH, Kim YJ, Kim YG, Joh TH, Beal MF, and Kim YS. Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. The Journal of biological chemistry. 2011;286(16):14168-77.
30. Choi DH, Hwang O, Lee KH, Lee J, Beal MF, and Kim YS. DJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell death. Antioxidants & redox signaling. 2011;14(11):2137-50.
31. Cristovao AC, Choi DH, Baltazar G, Beal MF, and Kim YS. The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxidants & redox signaling. 2009;11(9):2105-18.
32. Cho Y, Son HJ, Kim EM, Choi JH, Kim ST, Ji IJ, et al. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotoxicity research. 2009;16(4):361-71.
33. Song DY, Yang YC, Shin DH, Sugama S, Kim YS, Lee BH, et al. Axotomy-induced dopaminergic neurodegeneration is accompanied with c-Jun phosphorylation and activation transcription factor 3 expression. Experimental neurology. 2008;209(1):268-78.
34. Choi DH, Kim EM, Son HJ, Joh TH, Kim YS, Kim D, et al. A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. Journal of neurochemistry. 2008;106(1):405-15.
35. Park YK, Chung YS, Kim YS, Kwon OY, and Joh TH. Inhibition of gene expression and production of iNOS and TNF-alpha in LPS-stimulated microglia by methanol extract of Phellodendri cortex. International immunopharmacology. 2007;7(7):955-62.
36. Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007;21(1):179-87.
37. Jung HW, Chung YS, Kim YS, and Park YK. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Experimental & molecular medicine. 2007;39(6):715-21.
38. Kim YS, and Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Experimental & molecular medicine. 2006;38(4):333-47.
39. Cho BP, Song DY, Sugama S, Shin DH, Shimizu Y, Kim SS, et al. Pathological dynamics of activated microglia following medial forebrain bundle transection. Glia. 2006;53(1):92-102.
40. Kim YS, Kim SS, Cho JJ, Choi DH, Hwang O, Shin DH, et al. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2005;25(14):3701-11.
41. Park KC, Chung KC, Kim YS, Lee J, Joh TH, and Kim SY. Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia. Biochemical and biophysical research communications. 2004;323(3):1055-62.
42. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, et al. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. The Journal of biological chemistry. 2004;279(51):53725-35.
43. Sugama S, Cho BP, Degiorgio LA, Shimizu Y, Kim SS, Kim YS, et al. Temporal and sequential analysis of microglia in the substantia nigra following medial forebrain bundle axotomy in rat. Neuroscience. 2003;116(4):925-33.
44. Cho BP, Sugama S, Shin DH, DeGiorgio LA, Kim SS, Kim YS, et al. Microglial phagocytosis of dopamine neurons at early phases of apoptosis. Cellular and molecular neurobiology. 2003;23(4-5):551-60.
45. DeGiorgio LA, Shimizu Y, Chun HS, Kim YS, Sugama S, Son JH, et al. Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy. Brain research. 2002;938(1-2):38-44.
46. Cho S, Park EM, Kim Y, Liu N, Gal J, Volpe BT, et al. Early c-Fos induction after cerebral ischemia: a possible neuroprotective role. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2001;21(5):550-6.
47. Cho S, Kim Y, Cruz MO, Park EM, Chu CK, Song GY, et al. Repression of proinflammatory cytokine and inducible nitric oxide synthase (NOS2) gene expression in activated microglia by N-acetyl-O-methyldopamine: protein kinase A-dependent mechanism. Glia. 2001;33(4):324-33.
48. Sugama S, Kim Y, Baker H, Tinti C, Kim H, Joh TH, et al. Tissue-specific expression of rat IL-18 gene and response to adrenocorticotropic hormone treatment. J Immunol. 2000;165(11):6287-92.
49. Conti B, Sugama S, Kim Y, Tinti C, Kim H, Baker H, et al. Modulation of IL-18 production in the adrenal cortex following acute ACTH or chronic corticosterone treatment. Neuroimmunomodulation. 2000;8(1):1-7.
50. Conti B, Park LC, Calingasan NY, Kim Y, Kim H, Bae Y, et al. Cultures of astrocytes and microglia express interleukin 18. Brain research Molecular brain research. 1999;67(1):46-52.